Curative Effectiveness of Gamma Globulin and Azithromycin in Treating Severe Pediatric Mycoplasma Pneumoniae Pneumonia and Influence on the Levels of CRP T lymphocyte Subsets and Immunoglobulin
XIE Cheng, FAN Yinghong, AI Tao, et al
Women and Children's Hospital Affiliated to Medical College of University of Electronic Science and Technology / The Center of Women and Children in Chengdu, Sichuan Chengdu 610091, China
Abstract：Objective: To explore the curative effectiveness of gamma globulin and azithromycin in treating severe pediatric mycoplasma pneumoniae pneumonia, and to analyze their effects on the levels of CRP, T lymphocyte subsets and immunoglobulin.Methods: 190 cases admitted in our hospital from February 2017 to February 2019 were selected prospectively and randomly divided into 2 groups with random number table method.The control group (n=95) was treated with azithromycin, and the observation group (n=95) was administered gamma globulin combined with azithromycin.Records were made of clinical effect of two groups (time index, pulmonary function index).Analysis was made on changes of CRP, immunoglobulin and T cells before and after interventional treatment.And the security of both treatments was compared.Results: Clinical effect was found better for the observation group, whose fever clearance time, the disappearance time of cough and pulmonary rales ,and length of hospital stay were respectively (2.58±0.78)d, (2.47±0.63)d, (3.95±1.15)d, (7.87±1.28) d, significantly lower than in the control group (3.72±1.31)d, (4.84±1.41) d, (6.35±2.25) d, (10.28±3.28)d, and the difference was statistically significant (P<0.05).FEV1, FVC and MMEF in the observation group were (65.41±6.14) %, (60.30±5.43) % and (65.96±7.19)%, respectively, which were significantly higher than those in the control group (51.67±5.46) %, (55.55±6.74) % and (52.25±7.25) %, with statistically significant differences (P<0.05).CRP and CD8+ were significantly decreased in both groups after treatment, and CD4+, CD4+/CD8+, IgA, IgG and IgM were significantly increased (P<0.05).After treatment, CRP and CD8+ in the observation group were (10.86±5.72) mg/L and (28.64±2.44) %, respectively, which were significantly lower than those in the control group (19.32±6.09) mg/L and (30.80±4.30) %, with statistically significant differences (P<0.05).CD4+, CD4+/CD8+, IgA, IgG and IgM of the observation group were (49.39±6.95) %, (1.88±0.65) %, (2.95±0.49) g/L, (13.37±2.80) g/L, (1.63±0.38) g/L, respectively, higher than the control group (44.87±6.31) %, (1.51±0.53) %, (2.41±0.48) g/L, (11.06±2.18) g/L, (1.34±0.38) g/L, and the differences were statistically significant (P<0.05).In addition, the incidence of adverse reactions in both groups was compared, and the difference was not statistically significant (P>0.05).Conclusion: Immunoglobulin combined with azithromycin can significantly improve the clinical effect, improve the function of T-lymphocyte subsets and increase the expression level of immunoglobulin in children.
谢诚, 樊映红, 艾涛, 刘燕茹, 王丽, 罗荣华, 赖华. 丙种球蛋白与阿奇霉素治疗小儿重症肺炎支原体肺炎的效果及对CRP T淋巴细胞亚群免疫球蛋白水平的影响[J]. 河北医学, 2020, 26(9): 1446-1450.
XIE Cheng, FAN Yinghong, AI Tao, et al. Curative Effectiveness of Gamma Globulin and Azithromycin in Treating Severe Pediatric Mycoplasma Pneumoniae Pneumonia and Influence on the Levels of CRP T lymphocyte Subsets and Immunoglobulin. HeBei Med, 2020, 26(9): 1446-1450.
[1] Parrott G L, Kinjo T, Fujita J. A compendium for mycoplasma pneumoniae[J]. Frontiers in Microbiology, 2016, 7(e196):513. [2] Yimeniciolu S, Yakut A, Ekici A, et al. Mycoplasma pneumoniae infection with neurologic complications[J]. Iranian Journal of Pediatrics, 2014, 24(5):647~651. [3] 胡亚美,江载芳.诸福棠实用儿科学[M].人民卫生出版社,2002.1204~1205. [4] Shu L H, Xu J J, Wang S, et al. Distribution of pathogenic microorganisms and its relationship with clinical features in children with community-acquired pneumonia[J]. Chinese Journal of Contemporary Pediatrics, 2015, 17(10):1056~1061. [5] Wang M, Wang Y, Yan Y, et al. Clinical and laboratory profiles of refractory mycoplasma pneumoniae pneumonia in children - international journal of infectious diseases[J]. International Journal of Infectious Diseases Ijid Official Publication of the International Society for Infectious Diseases, 2014, 29(C):18~23. [6] Chaudhry R, Ghosh A, Chandolia A. Pathogenesis of mycoplasma pneumoniae: an update.[J]. Indian Journal of Medical Microbiology, 2016, 34(1):7. [7] Ding L , Ji W , Sun H M , et al. Association of T lymphocyte subsets and allergens with mycoplasma pneumoniae infection complicated by wheezing in infants and young children[J]. Chinese Journal of Contemporary Pediatrics, 2016, 18(12):1254. [8] Kwon J H, Seo W H, Yoo Y, et al. Serum total Immunoglobulin and mycoplasma pneumonia[J]. Journal of Allergy & Clinical Immunology, 2018, 141(2):AB20. [9] Lee H, Yun K W, Lee H J, et al. Antimicrobial therapy of macrolide-resistant mycoplasma pneumoniae pneumonia in children.[J]. Expert review of anti-infective therapy, 2017, 16(1):23~34.
2020, Vol. 26 
冀公网安备13080202000677号